- Page 1:
TRANSMUCOSAL NASAL DRUG DELIVERY Sy
- Page 5 and 6:
Acknowledgments At the Hospital Pha
- Page 7:
Index EXPERIMENTAL SECTION 5 Projec
- Page 11 and 12:
Summary Summary Transmucosal nasal
- Page 13:
Summary Project III: In this random
- Page 17:
THEORETICAL SECTION
- Page 20 and 21:
1. Nasal drug delivery 1.2 Transmuc
- Page 22 and 23:
1. Nasal drug delivery 1.3 Challeng
- Page 25 and 26:
2. Impact of anatomy and physiology
- Page 27 and 28:
2. Impact of anatomy and physiology
- Page 29 and 30:
2. Impact of anatomy and physiology
- Page 31 and 32:
3. Midazolam 3 Midazolam 3.1 Physic
- Page 33 and 34:
3. Midazolam 3.2.1 Indications and
- Page 35 and 36:
3. Midazolam Administration of high
- Page 37 and 38:
3. Midazolam gastrointestinal tract
- Page 39 and 40:
4. Compounding of nasal midazolam p
- Page 41 and 42:
4. Compounding of nasal midazolam p
- Page 43 and 44:
4. Compounding of nasal midazolam p
- Page 45 and 46:
4. Compounding of nasal midazolam p
- Page 47 and 48:
4. Compounding of nasal midazolam p
- Page 49:
4. Compounding of nasal midazolam p
- Page 53 and 54:
5. Project I: Development of prepar
- Page 55 and 56:
5. Project I: Development of prepar
- Page 57 and 58:
5. Project I: Development of prepar
- Page 59 and 60:
5. Project I: Development of prepar
- Page 61 and 62: 5. Project I: Development of prepar
- Page 63 and 64: 5. Project I: Development of prepar
- Page 65 and 66: 5. Project I: Development of prepar
- Page 67: 5. Project I: Development of prepar
- Page 70 and 71: 6. Project II: Pharmacokinetic of t
- Page 72 and 73: 6. Project II: Pharmacokinetic of t
- Page 74 and 75: 6. Project II: Pharmacokinetic of t
- Page 76 and 77: 6. Project II: Pharmacokinetic of t
- Page 78 and 79: 6. Project II: Pharmacokinetic of t
- Page 80 and 81: 6. Project II: Pharmacokinetic of t
- Page 82 and 83: 6. Project II: Pharmacokinetic of t
- Page 84 and 85: 6. Project II: Pharmacokinetic of t
- Page 86 and 87: 6. Project II: Pharmacokinetic of t
- Page 88 and 89: 6. Project II: Pharmacokinetic of t
- Page 91 and 92: 7. Project III: Transmucosal nasal
- Page 93 and 94: 7. Project III: Transmucosal nasal
- Page 95 and 96: 7. Project III: Transmucosal nasal
- Page 97 and 98: 7. Project III: Transmucosal nasal
- Page 99 and 100: 7. Project III: Transmucosal nasal
- Page 101 and 102: 7. Project III: Transmucosal nasal
- Page 103: 7. Project III: Transmucosal nasal
- Page 106 and 107: 8 Overall discussion pharmacokineti
- Page 108 and 109: 8 Overall discussion considered as
- Page 111: Appendix
- Page 115 and 116: 10 Appendix 10.2.3 Accelerated stab
- Page 117 and 118: 10 Appendix 10.2.5 Specification: M
- Page 119 and 120: 10 Appendix 10.2.7 Specification: C
- Page 121 and 122: 10 Appendix 10.2.8 Specification: C
- Page 123 and 124: 10 Appendix 10.2.10 Stability repor
- Page 125 and 126: 10 Appendix 10.2.11 Stability repor
- Page 127 and 128: 10 Appendix 10.2.12 Stability repor
- Page 129 and 130: 10 Appendix 10.2.13 Stability repor
- Page 131 and 132: 10 Appendix 10.2.14 Stability repor
- Page 133 and 134: 10 Appendix 10.2.15 Stability repor
- Page 135 and 136: 10 Appendix Project II 10.3.1 Study
- Page 137 and 138: 10 Appendix Katja Suter-Zimmermann
- Page 139 and 140: 10 Appendix Katja Suter-Zimmermann
- Page 141 and 142: 10 Appendix Katja Suter-Zimmermann
- Page 143 and 144: 10 Appendix Katja Suter-Zimmermann
- Page 145 and 146: 10 Appendix Katja Suter-Zimmermann
- Page 147 and 148: 10 Appendix Katja Suter-Zimmermann
- Page 149 and 150: 10 Appendix Katja Suter-Zimmermann
- Page 151 and 152: 10 Appendix Katja Suter-Zimmermann
- Page 153 and 154: 10 Appendix 1.3.3 Case report form:
- Page 155 and 156: 10 Appendix Katja Suter-Zimmermann
- Page 157 and 158: 10 Appendix Katja Suter-Zimmermann
- Page 159 and 160: 10 Appendix Frequency 10.3.6 Intens
- Page 161 and 162: 10 Appendix Identification midazola
- Page 163 and 164:
10 Appendix Identification midazola
- Page 165 and 166:
10 Appendix Identification midazola
- Page 167 and 168:
10 Appendix Identification midazola
- Page 169 and 170:
10 Appendix 10.3.9 Nasal delivery o
- Page 171 and 172:
10 Appendix 10.4. Project III 10.4.
- Page 173 and 174:
10 Appendix Katja Suter-Zimmermann
- Page 175 and 176:
10 Appendix 10.4.4 Instruction mate
- Page 177 and 178:
10 Appendix Katja Suter-Zimmermann
- Page 179 and 180:
10 Appendix Katja Suter-Zimmermann
- Page 181 and 182:
10 Appendix Katja Suter-Zimmermann
- Page 183:
10 Appendix Katja Suter-Zimmermann
- Page 186 and 187:
11 References Cote, C.J., Md, I.T.
- Page 188 and 189:
11 References Griffith, N., S. Howe
- Page 190 and 191:
11 References Lahat, E., M. Goldman
- Page 192 and 193:
11 References Mygind, N. and R. Dah
- Page 194 and 195:
11 References Tschirch, F.T., K. Go
- Page 196:
12 Curriculum vitae During my acade